[go: up one dir, main page]

Blauhut et al., 1982 - Google Patents

Substitution therapy with an antithrombin III concentrate in shock and DIC

Blauhut et al., 1982

Document ID
683801668037391583
Author
Blauhut B
Necek S
Vinazzer H
Bergmann H
Publication year
Publication venue
Thrombosis Research

External Links

Snippet

In 15 patients admitted to the Intensive Care Unit for shock and with signs of DIC, Antithrombin III (AT III) was substituted. Immediately after the first blood sampling, 1,000 units of AT III was given. This was followed by 500 units AT III after 24 h and after 48 h. A …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Similar Documents

Publication Publication Date Title
Blauhut et al. Substitution therapy with an antithrombin III concentrate in shock and DIC
Vinazzer Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation
Sakariassen et al. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium
Sas et al. Abnormal antithrombin III (antithrombin III ‘Budapest’) as a cause of a familial thrombophilia
Wada et al. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries
HENRIKSSON et al. Factor XIII (fibrin stabilising factor) in Henoch‐Schönlein's purpura
Martin et al. Fresh frozen plasma supplement to massive red blood cell transfusion
Kumada et al. Comparative study on heparin and a synthetic thrombin inhibitor No. 805 (MD-805) in experimental antithrombin III-deficient animals
Mammen et al. Human antithrombin concentrates and experimental disseminated intravascular coagulation
Rapaport et al. The blood clotting properties of rabbit peritoneal leukocytes in vitro
Uchiba et al. Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation
Blauhut et al. Activity of antithrombin III and effect of heparin on coagulation in shock
Wada et al. Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation
Sterrenberg et al. Evidence of fibrinogen breakdown by leukocyte enzymes in a patient with acute promyelocytic leukemia
Tyigate et al. Metabolism and Distribution of Fibrinogen 11. FIBRINOGEN TURNOVER IN POLYCYTHAEMIA, THROMBOCYTOSIS, HAEMOPHILIA A, CONGENITAL AFIBRINOGENAEMIA AND DURING STREPTOKINASE THERAPY
Rapaport Blood coagulation and its alterations in hemorrhagic and thrombotic disorders
Cronberg Effect of fibrinolysis on adhesion and aggregation of human platelets
Yanofsky et al. The multiple coagulopathies of biliary atresia
Bruning et al. Prothrombal: a new concentrate of human prothrombin complex for clinical use
Sakata et al. Treatment of DIC with antithrombin III concentrates
Ueyama et al. Progressing ischemic stroke in a homozygote with variant antithrombin III.
Patrassi et al. Fibrinolytic study in plasma and ascitic fluid of cirrhotic patients before and after ascites concentration; reinfusion technique
Weiss et al. Survival of transfused factor VIII in hemophilic patients treated with epsilon aminocaproic acid
Alegre et al. Effect of hemodialysis on protein C levels
Chan et al. Hypofibrinogenemia due to increased fibrinolysis in two patients with acute promyelocytic leukemia